...
首页> 外文期刊>Die Pharmazie >Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacro-limus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend (R) SF PH4 oral suspensions
【24h】

Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacro-limus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend (R) SF PH4 oral suspensions

机译:胆碱钙化醇,氟哌啶醇,盐酸丙咪嗪,左旋多巴/卡比多巴,劳拉西m,盐酸米诺环素,他克莫司一水合物,特比萘芬,盐酸曲马多和缬沙坦的相容性在SyrSpend(SF)PH4口服混悬液中

获取原文
获取原文并翻译 | 示例
           

摘要

A challenge with compounding oral liquid formulations is the limited availability of data to support the physical, chemical and microbiological stability of the formulation. This poses a patient safety concern and a risk for medication errors. The objective of this study was to evaluate the compatibility of the following active pharmaceutical ingredients (APIs) in 10 oral suspensions, using SyrSpend (R) SF PH4 (liquid) as the suspending vehicle: cholecalciferol 50,000 IU/mL, haloperidol 0.5 mg/mL, imipramine hydrochloride 5.0 mg/mL, levodopa/carbidopa 5.0/1.25 mg/mL, lorazepam 1.0 mg/mL, minocycline hydrochloride 10.0 mg/mL, tacrolimus monohydrate 1.0 mg/mL, terbinafine 25.0 mg/mL, tramadol hydrochloride 10.0 mg/mL and valsartan 4.0 mg/mL. The suspensions were stored both refrigerated (2-8 degrees C) and at controlled room temperature (20-25 degrees C). This is the first stability study for these APIs in SyrSpend (R) SF PH4 (liquid). Further, the stability of haloperidol,ilmipramine hydrochloride, minocycline, and valsartan in oral suspension has not been previously reported in the literature. Compatibility was assessed by measuring percent recovery at varying time points throughout a 90 days period. Quantification of the APIs was performed by high performance liquid chromatography (HPLC-UV). Given the percentage of recovery of the APIs within the suspensions, the beyond-use date of the final preparations was found to be at least 90 days for most suspensions both refrigerated and at room temperature. Exceptions were: Minocycline hydrochloride at both storage temperatures (60 days), levodopa/carbidopa at room temperature (30 days), and lorazepam at room temperature (60 days). This suggests that compounded suspensions of APIs from different pharmacological classes in SyrSpend (R) SF PH4 (liquid) are stable.
机译:混合口服液体制剂的挑战在于,数据不足以支持制剂的物理,化学和微生物稳定性。这带来了患者安全隐患和药物错误的风险。这项研究的目的是评估以下活性药物成分(API)在10种口服混悬液中的相容性,使用SyrSpend(SF)SF PH4(液体)作为悬浮媒介:胆钙化固醇50,000 IU / mL,氟哌啶醇0.5 mg / mL ,盐酸丙咪嗪5.0 mg / mL,左旋多巴/卡比多巴5.0 / 1.25 mg / mL,劳拉西m 1.0 mg / mL,盐酸米诺环素10.0 mg / mL,他克莫司一水合物1.0 mg / mL,特比萘芬25.0 mg / mL,盐酸曲马多10.0 mg / mL和缬沙坦4.0 mg / mL。将悬浮液冷藏(2-8℃)和受控室温(20-25℃)下储存。这是针对这些API在SyrSpend(R)SF PH4(液体)中进行的首次稳定性研究。此外,氟哌啶醇,盐酸丙咪嗪,米诺环素和缬沙坦在口服混悬剂中的稳定性尚未在文献中报道。通过在整个90天内测量不同时间点的回收百分比来评估兼容性。通过高效液相色谱(HPLC-UV)对API进行定量。给定悬浮液中API的回收百分比,对于大多数冷藏和室温悬浮液,最终制剂的停用日期至少为90天。例外情况是:在储存温度(60天),盐酸左旋多巴/卡比多巴在室温下(30天)和劳拉西m在室温下(60天)均为米诺环素盐酸盐。这表明来自不同药理学类别的API在SyrSpend SF PH4(液体)中的复合悬浮液是稳定的。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号